

Special Issue

Immunotherapy for Non-small Cell Lung Cancer

Message from the Guest Editors

Non-small cell lung cancer (NSCLC) is a disease with high mortality world-wide. However, treatment approaches have been improving in the last few decades. Several immune checkpoints inhibitors acquired an important role in the clinical practice either in the adjuvant or in metastatic setting. Thus, this Special Issue will focus in the basic, translational, and clinical research in the field of immunotherapy in order to understand the future trends in this field.

Guest Editors

Prof. Dr. Ramon Andrade De Mello

1. Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK
2. Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK
3. Post-Graduation Program in Medicine, Nine of July University, (UNINOVE), São Paulo 01525-001, SP, Brazil

Prof. Nam P. Nguyen

Department of Radiation Oncology, Howard University College of Medicine, Washington, DC, USA

Deadline for manuscript submissions

closed (12 November 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/50947

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)